Alan L Parker is a Professor of Translational Virotherapies and the Head of the Section of Solid Cancers, Division of Cancer and Genetics at Cardiff University. He performed his PhD at the CRUK Institute for Cancer Studies at the University of Birmingham and he completed his thesis entitled "Development of Peptide Targeted Gene Delivery Systems" in 2003. In 2007, he was awarded a prestigious RSE Personal Fellowship to generate safer and more efficacious Ad-based vectors for in vivo applications. In 2010–2013, he was a BHF-funded Senior Scientist. In 2013, his desire to apply his adenoviral knowledge in the cancer setting resulted in his relocation to Cardiff University as a Lecturer and group leader.  In 2014, he was promoted to Senior Lecturer, to Reader in 2018, and to Professor of Translational Virotherapies in 2020. Since 2020, he has led the targeted therapeutic programme of the HCRW-funded Wales Cancer Research Centre. He has been an elected board member of the British Society for Gene and Cell Therapy since 2014 and has been Treasurer of the society since 2020. His research interests include gene therapy, non-viral gene transfer, cancer, oncology, virotherapy, cardiovascular disorders, targeting, phage display, atherosclerosis, novel platforms for gene delivery, nanoparticles, drug delivery, immunotherapy, oncolytic viruses, tumor biology, invasion, and metastasis.